Evidence map›Paper›PMID 17615545›Full record

ArticleMolecular vision2007

Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity.

Yuta Saito, Pete Geisen, Abhineet Uppal, M Elizabeth Hartnett

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 99 citations in OpenAlex.

  1. Review
  2. [Advances in pharmacological research for retinopathy of prematurity].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Intravitreal Delivery of VEGF-ACurrent eye research · 2019
    Article
  12. Article
  13. Article
  14. A review of treatment for retinopathy of prematurity.Expert review of ophthalmology · 2019
    Article
  15. The progress of prophylactic treatment in retinopathy of prematurity.International journal of ophthalmology · 2018
    Review
  16. In Vivo Angiography Quantifies Oxygen-Induced Retinopathy Vascular Recovery.Optometry and vision science : official publication of the American Academy of Optometry · 2016
    Article
  17. Article
  18. Review
  19. Review
  20. 17β-estradiol ameliorates oxygen-induced retinopathy in the early hyperoxic phase.Biochemical and biophysical research communications · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuta SaitoDepartment of Ophthalmology, University of North Carolina, Chapel Hill, NC 27599-7041, USA. s-yuta@med.showa-u.ac.jp
Pete Geisen
Abhineet Uppal
M Elizabeth Hartnett
University of North Carolina at Chapel Hill · US

Funding

Mechanisms of Angiogenesis of Retinopathy of PrematurityR01EY015130 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mary Elizabeth Ruth Hartnett · 2005 to 2026
$7.6M
NEI NIH HHS R01 EY015130
6 · The paper itself

Abstract

purposeTo study the mechanisms of action of the antioxidants, n-acetylcysteine (NAC), and the nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase oxidase inhibitor, apocynin, on intravitreous neovascularization (IVNV), and retinal avascularity in a rat model of retinopathy of prematurity (ROP).

methodsNewborn rats exposed to oxygen-induced retinopathy underwent intraperitoneal (IP) injections of NAC (150 mg/kg) at post-natal day (p)2, p6, p10 (early NAC-treated), or p12 through p17 (late NAC-treated), apocynin (10 mg/kg) from p12 through p17, or phosphate buffered saline (PBS; controls). Lipid hydroperoxide (LHP) was measured in early NAC-treated oxygen-induced retinopathy (OIR) at p7, p14 and p18. Pups were placed in room air at p14. At p18, retinal flat mounts were scored for IVNV and avascular/total retinal area, or retinas were assayed for cleaved caspase-3 and vascular endothelial growth factor (VEGF) protein. In non-injected OIR pups, retinas were assayed for gp91(phox). Cryosections were stained with isolectin B4, cleaved caspase-3, CD68, CD31, gp91(phox), neuron-glial antigen 2 (NG-2), or anti-glial fibrillary acidic protein (GFAP) and visualized with confocal microscopy.

resultsLHP increased over time in retinas from OIR exposed pups in association with IVNV. Early NAC-treated retinas had significantly reduced LHP compared to PBS-control at p18 (p<0.012). However, neither early nor late treatment with NAC had an effect on IVNV or retinal avascularity. Although apocynin had no effect on IVNV, it reduced both avascular retina (p=0.017) and retinal cleaved caspase-3 determined by western blot (p=0.021). In cryosections from OIR eyes, cleaved caspase-3 positive cells co-labeled with some lectin-stained vessels, NG2 labeled cells, and with GFAP positive cells in the inner nuclear layer. We found that the intravascular expression of gp91(phox) co-localized mostly with CD31 and some CD68 positive cells.

conclusionsOur results do not support the antioxidant properties of NAC as effective in reducing IVNV or avascular retina in the 50/10 OIR rat model. Apocynin reduced avascularity and apoptosis in the OIR model perhaps through pathways triggered by ROS generation but upstream from LHP production. Further study and consideration may be given to apocynin or NAD(P)H oxidase inhibitors as adjunctive therapy for ROP to reduce the avascular retina.

Indexed as

Disease Models, AnimalAcetophenonesAcetylcysteineAnimalsAnimals, NewbornApoptosisCaspase 3CryoultramicrotomyEndothelial CellsInjections, IntraperitonealLipid PeroxidesMembrane GlycoproteinsNADPH Oxidase 2NADPH OxidasesNeurogliaOxygenAcetophenonesacetovanilloneAcetylcysteineCaspase 3Cybb protein, ratLipid PeroxidesMembrane GlycoproteinsNADPH Oxidase 2NADPH OxidasesOxygenVascular Endothelial Growth Factor A

Identifiers

PMID17615545
PMCPMC2770201
OpenAlexW1548659316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.